Fatal cardiac ischaemia associated with prolonged desflurane anaesthesia and administration of exogenous catecholamines
Related Experiment Video
Updated: Oct 24, 2026

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice
Published on: April 19, 2011
1Department of Anaesthesia, Royal Group of Hospitals, Belfast, United Kingdom.
Purpose:
Four cardiac ischaemic events are reported during and after prolonged anaesthesia with desflurane.
Clinical Features:
We have evaluated desflurane in 21 consecutive patients undergoing advanced head and neck reconstructive surgery. Four deaths occurred which were associated with cardiac ischaemic syndromes either during or immediately after operation. All patients in the study received a similar anaesthetic. This comprised induction with propofol and maintenance with alfentanil and desflurane in oxygen-enriched air. Inotropic support (either dopamine or dobutamine in low dose, 5 micrograms.kg.min-1) was provided as part of the anaesthetic technique in all patients. Critical cardiovascular incidents were observed in each of the four patients during surgery. These were either sudden bradycardia or tachycardia associated with ST-segment electrocardiographic changes. The four patients who died had a documented past history of coronary heart disease and were classified American Society of Anesthesiologists (ASA) II or III. One patient (#2) did not survive anaesthesia and surgery and the three others died on the first, second and twelfth postoperative days. Enzyme increases (CK/CK-MB) were available in three patients and confirmed myocardial ischaemia.
Conclusion:
These cases represent an unexpected increase in the immediate postoperative mortality for these types of patients and this anaesthetic sequence.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Introduction Cardiac Emergencies
Coronary Artery Disease III: Clinical Manifestations
Cardiopulmonary Resuscitation III: AED Use
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Heart Failure Drugs: Inotropic Agents
